Date post: | 14-Dec-2015 |
Category: |
Documents |
Upload: | khalid-hawkey |
View: | 216 times |
Download: | 2 times |
1 Q1/15 – all rights reserved
Zestagen S.A.
Services Summary
2015
v6/Q1 15
Nassos Alevizopoulos, PhD, MBA
Managing Partner
2 Q1/15 – all rights reserved
Meta-plasis (trans-formation) at a glance
boutique biotech & pharma consulting
Support project mgmt. or investment decisions
Sector dedication
Analyze, integrate & transform
Extreme focus on science (Medline, WIPO)
Commercial & financial info (databases)
Excellent value for money
Minuscule team (EU/US) with broad international network
Consultants with active executive roles
Direct access to specialized associated networks
We understand & get down into the project’s core science
Virtual operations (timesheet, availability)
Rapid turnaround
what we do
how we do it
why us?
3 Q1/15 – all rights reserved
Key Metaplasis people
Nassos Alevizopoulos, PhD, MBA Kostas Alevizopoulos, PhD Andrei Lyne, MBA
CH CH USA
• 20y of experience in biopharmaceutical development (large molecules, devices)
• currently CEO of Zestagen SA (preclinical cancer mAb; CH)
• oversaw an orphan drug designation in pancreatic cancer
• COO/CEO positions in various biopharma companies (US/GR)
• cofounded startup companies
• Business Planning & Analysis with Novartis
• Brunner Prize for the best of 181 PhDs in Molecular Biology (Lausanne Univ.); also MBA from Lausanne
• 17y of experience in life sciences (drug development, small molecules, diagnostics)
• currently CEO of APIM Therapeutics AS (cancer biotech, Norway)
• partner at Ventac Partners
• previously CEO/CSO/Head of R&D in various biotech companies (US/CH/GR)
• cofounded startup companies
• Ph.D. in Molecular Oncology (Univ. of Lausanne)
• trained in European patent law (Univ. of Strasbourg)
• 12y with UBS Investment Bank in London & New York, most recently as Executive Director
• over 100 transactions across 25 countries for deals worth an aggregate $8 billion;
• currently CFO at Synpromics Ltd.
• Experience in biopharma, buy-side and sell-side M&A, IPOs, convertible bonds etc.
• BA from Oxford Univ. (Baker Scholarship)
• MBA in finance from New York Univ. (Directors Fellowship)
4 Q1/15 – all rights reserved
1. Metaplasis can assist academic institutions with tech transfer
Technology appraisal
Scientific analysis
Intellectual Property / Freedom to Operate (FTO) analysis
SWOT analysis
Evaluation of partnering potential
Tech valuation
Tech agreement drafting (Sponsored Research, CRADA)
Collaboration with Univ. Tech Transfer Office (TTO)
academicdiscovery
Commercializable?
TTOTTO
Seed $angels
Spinoffformation
5 Q1/15 – all rights reserved
1. Metaplasis can assist academic institutions with tech transfer (cont’ed)
Case study 1: NewCo formation around cutting-edge cancer IP
Unique mAb against cancer
IP licensed from a European Institution to NewCo
Seed investor found
Case study 2: a Scandinavian University
Position novel anti-cancer therapeutics
Case study 3: mandate from a group of Canadian investors (on going)
Scout for promising tech in N. America for NewCo formation
Case study 4: technology appraisal for a Chinese biopharma company
Report & annexes delivered in 10 business days
6 Q1/15 – all rights reserved
2. Metaplasis can assist with preclinical drug development effort
Drawing from hands-on experience (running our own companies) we can
assist with:
Preclinical development plan generation
Outsourcing decisions (chose relevant Contract-Research Organizations)
Scientific & regulatory preparation for Guidance Regulator meetings (Scientific
Advice, Protocol Assistance, IND/IMPD)
Case studies
Assist a clinical CRO to attract an assignment by a vaccine developer
for preclinical regulatory assistance
7 Q1/15 – all rights reserved
Sample Preclinical
Development Plan
Time
Actions
Cost
Incumbent
Single Page format
2. Metaplasis can assist with preclinical drug development effort (cont’ed)
8 Q1/15 – all rights reserved
3. Metaplasis can assist with investment decisions
Product/company
valuations
risk-adjusted
NPV
comparables
EV/EBITDA
Case study 1:
Estimate value of a
Scandinavian
biotech company
with rNPV
Case study 2
EV/EBITDA analysis
of a Greek
healthcare takeover
target
c2: EV/EBITDA
c1: rNPV
9 Q1/15 – all rights reserved
4. Metaplasis can assist with business development of market-ready products
Strategy development for market-ready (i.e. approved) products entering new
geographic markets
Identification of potential partners (licensors, buyers/sellers)
Development of client company materials (non-conf & conf)
Deal Structures & Value Sharing (e.g. up-fronts vs. delayed payments)
Network in Balkans, MENA, CIS, some EU countries, some States
pharmaceuticals, medical devices, neutraceuticals, herbals
10 Q1/15 – all rights reserved
Case: ranking candidate Greek distributors for an Asian company
4. Metaplasis can assist with business development of market-ready products (c’ed)
11 Q1/15 – all rights reserved
Summary of Metaplasis Services
1. Technology appraisals (academic institutions, biotech, investors…)
2. Assistance with preclinical drug development (biotech)
3. Assistance with investment decisions (biotech, investors)
4. Business development (market-ready products for pharma, devices etc.)
12 Q1/15 – all rights reserved
Zestagen S.A.
Thank You
Nassos Alevizopoulos, PhD, MBA
Managing Partner